Novo owner backs Swiss biotech company Asceneuron in $100 million round
Swiss biotech company Asceneuron said Tuesday it has raised $100 million from investors including controlling shareholder Wegovy maker Novo Nordisk to fund clinical development of its drug to treat Alzheimer’s disease.
POPULAR POSTS
Portugal declares risk as wildfires hit the north of the country
September 17, 2024
UK to appoint nature envoy
September 17, 2024
Death tolls rises as Central Europe floods
September 17, 2024
LIVE STREAM